國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁 到查詢結果 [ subject:"Drugs." ]

切換: 標籤 | MARC模式 | ISBD

Communicating about risks and safe u...

Bahri, Priya.

Communicating about risks and safe use of medicinesreal life and applied research /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Communicating about risks and safe use of medicinesedited by Priya Bahri.
其他題名:	real life and applied research /
其他作者:	Bahri, Priya.
出版者:	Singapore :Springer Singapore :2020.
面頁冊數:	xxx, 504 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Communication in pharmacy.
電子資源:	https://doi.org/10.1007/978-981-15-3013-5
ISBN:	9789811530135$q(electronic bk.)

Communicating about risks and safe use of medicinesreal life and applied research /
Communicating about risks and safe use of medicinesreal life and applied research /[electronic resource] :edited by Priya Bahri. - Singapore :Springer Singapore :2020. - xxx, 504 p. :ill., digital ;24 cm.

Foreword (Baruch Fischhoff) -- Preface: Guide for readers (Priya Bahri) -- Authors' biographical notes -- Overview of contents in chapters -- 1. A multilayered research framework for humanities and epidemiology of medicinal product risk communication (Priya Bahri) -- Part I: Medicines in real life as communication challenges. 2. Hormonal contraceptives - Communication for risk awareness and informed choice, or a public scare? (Barbara Mintzes, Teresa Alves, with a contribution from Priya Bahri) -- 3. COX-2 inhibitors - Communication of accumulating risk evidence and a product withdrawal (Amy Rogers, Kerr Grieve, Thomas M MacDonald, with a contribution from Sergio Nishioka) -- 4. Isotretinoin - Communication for preventing birth defects and alerting of an uncertain risk of suicide (Ineke (HJMJ) Crijns) -- 5. Pandemic influenza vaccines - Communication of benefits, risks and uncertainties (Glen J Nowak, Emilie Karafillakis, Heidi Larson) -- Part II: Tackling the challenges - Methods for medicinal product risk communication research. 6. Ethical frameworks (Ghislaine van Thiel) -- 7. The cognitive and behavioural sciences (Sara Rubinelli, Nicola Diviani, Maddalena Fiordelli) -- 8. The social sciences (Brian Taylor, Anne Moorhead) -- 9. Rhetoric and science & technology studies (Mathias Møllebæk) -- 10. Media science and practice (Glen J Nowak, Michael A Cacciatore) -- 11. Social media research (Nabarun Dasgupta, Carly Winokur, Carrie E Pierce) -- 12. Design science with a focus on user-centred evaluation of written information (Jorg Fuchs) -- 13. Dissemination & implementation science (Elaine Morrato, Meredith Smith) -- 14. Pharmacoepidemiology (Bert (HGM) Leufkens) -- 15. Legal frameworks (Burkhard Strater) -- 16. From passive to active - Patients as contributors to medicinal product risk communication research (François Houÿez) -- Afterword: The dimension of communicating medicine risks in low- and middle-income countries (Nilima A Kshirsagar)

At the core of this book lies the question how to approach medicines, risks and communication as a researcher - or anybody planning and evaluating a communication intervention, or wanting to understand communication events in private and the media. With a view to tackle current shortcomings of communication systems and processes for improved implementation, patient satisfaction and health outcomes, a multilayered approach is presented. This combines multiple data types and methods to obtain a wider and deeper understanding of the major parties and their interactions, as well as the healthcare, social and political contexts of information flows, how they interfere and which impact they have. Illustrated with real life experiences of safety concerns with medicines, worldwide active experts discuss the methods and contributions their disciplines can offer. With considerations on terminologies, tabulated overviews on communication types and outcomes, a patient-centred vision and plain language for non-medical readers, the book creates a platform for multidisciplinary collaborations amongst researchers as well as practitioners from communications, healthcare, the social sciences and pharmacovigilance. Importantly, it advocates for an active role of patients and highlights the achievements and aspirations of patient organisations. Finally, the book suggests establishing an inclusive discipline of humanities and epidemiology of medicinal product risk communication to realise full research potential. The authors are driven by the curiosity for communication as the most human behaviour, and as good health is amongst the basic human needs, medicinal product risk communication is an exciting research field of high global relevance.

ISBN: 9789811530135$q(electronic bk.)

Standard No.: 10.1007/978-981-15-3013-5doiSubjects--Topical Terms:

303283
Communication in pharmacy.

LC Class. No.: RS56 / .C666 2020

Dewey Class. No.: 615.1

Communicating about risks and safe use of medicinesreal life and applied research /
LDR:04658nmm a2200325 a 4500 001 580645
003 DE-He213
005 20201030144053.0
006 m
007 cr
008 210105s2020
020 $a 9789811530135$q(electronic bk.)
020 $a 9789811530128$q(paper)
024 7 $a 10.1007/978-981-15-3013-5 $2 doi
035 $a 978-981-15-3013-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RS56 $b .C666 2020
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615.1 $2 23
090 $a RS56 $b .C734 2020
245 0 0 $a Communicating about risks and safe use of medicines $h [electronic resource] : $b real life and applied research / $c edited by Priya Bahri.
260 $a Singapore : $b Springer Singapore : $b Imprint: Adis, $c 2020.
300 $a xxx, 504 p. : $b ill., digital ; $c 24 cm.
505 0 $a Foreword (Baruch Fischhoff) -- Preface: Guide for readers (Priya Bahri) -- Authors' biographical notes -- Overview of contents in chapters -- 1. A multilayered research framework for humanities and epidemiology of medicinal product risk communication (Priya Bahri) -- Part I: Medicines in real life as communication challenges. 2. Hormonal contraceptives - Communication for risk awareness and informed choice, or a public scare? (Barbara Mintzes, Teresa Alves, with a contribution from Priya Bahri) -- 3. COX-2 inhibitors - Communication of accumulating risk evidence and a product withdrawal (Amy Rogers, Kerr Grieve, Thomas M MacDonald, with a contribution from Sergio Nishioka) -- 4. Isotretinoin - Communication for preventing birth defects and alerting of an uncertain risk of suicide (Ineke (HJMJ) Crijns) -- 5. Pandemic influenza vaccines - Communication of benefits, risks and uncertainties (Glen J Nowak, Emilie Karafillakis, Heidi Larson) -- Part II: Tackling the challenges - Methods for medicinal product risk communication research. 6. Ethical frameworks (Ghislaine van Thiel) -- 7. The cognitive and behavioural sciences (Sara Rubinelli, Nicola Diviani, Maddalena Fiordelli) -- 8. The social sciences (Brian Taylor, Anne Moorhead) -- 9. Rhetoric and science & technology studies (Mathias Møllebæk) -- 10. Media science and practice (Glen J Nowak, Michael A Cacciatore) -- 11. Social media research (Nabarun Dasgupta, Carly Winokur, Carrie E Pierce) -- 12. Design science with a focus on user-centred evaluation of written information (Jorg Fuchs) -- 13. Dissemination & implementation science (Elaine Morrato, Meredith Smith) -- 14. Pharmacoepidemiology (Bert (HGM) Leufkens) -- 15. Legal frameworks (Burkhard Strater) -- 16. From passive to active - Patients as contributors to medicinal product risk communication research (François Houÿez) -- Afterword: The dimension of communicating medicine risks in low- and middle-income countries (Nilima A Kshirsagar)
520 $a At the core of this book lies the question how to approach medicines, risks and communication as a researcher - or anybody planning and evaluating a communication intervention, or wanting to understand communication events in private and the media. With a view to tackle current shortcomings of communication systems and processes for improved implementation, patient satisfaction and health outcomes, a multilayered approach is presented. This combines multiple data types and methods to obtain a wider and deeper understanding of the major parties and their interactions, as well as the healthcare, social and political contexts of information flows, how they interfere and which impact they have. Illustrated with real life experiences of safety concerns with medicines, worldwide active experts discuss the methods and contributions their disciplines can offer. With considerations on terminologies, tabulated overviews on communication types and outcomes, a patient-centred vision and plain language for non-medical readers, the book creates a platform for multidisciplinary collaborations amongst researchers as well as practitioners from communications, healthcare, the social sciences and pharmacovigilance. Importantly, it advocates for an active role of patients and highlights the achievements and aspirations of patient organisations. Finally, the book suggests establishing an inclusive discipline of humanities and epidemiology of medicinal product risk communication to realise full research potential. The authors are driven by the curiosity for communication as the most human behaviour, and as good health is amongst the basic human needs, medicinal product risk communication is an exciting research field of high global relevance.
650 0 $a Communication in pharmacy. $3 303283
650 0 $a Drugs. $3 333245
650 1 4 $a Drug Safety and Pharmacovigilance. $3 701740
700 1 $a Bahri, Priya. $3 870537
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-981-15-3013-5
950 $a Medicine (Springer-11650)